Home  |  Contact

Cellosaurus LoVo-MEK-R (CVCL_V402)

Cell line name LoVo-MEK-R
Accession CVCL_V402
Resource Identification Initiative To cite this cell line use: LoVo-MEK-R (RRID:CVCL_V402)
Comments Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901).
Sequence variations Homozygous for ACVR2A p.Lys437fs*5 (c.1310delA) (from parent cell line).
APC p.Arg1114Ter (c.3340C>T), p.Met1431fs*42 (c.4289delC) and p.Arg2816Gln (c.8447G>A) (from parent cell line).
KRAS p.Gly13Asp (c.38G>A) (from parent cell line).
SMAD2 p.Ala292Val (c.875C>T) (from parent cell line).
Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0399 (LoVo)
Sex of cell Male
Age at sampling 56Y
Category Cancer cell line
Publications

PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010
Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P., Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H., Toy K., Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M., Moffat J., Belvin M., Lackner M.R.
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Mol. Cancer Ther. 11:1143-1154(2012)

Cross-references
Other Wikidata; Q54902903
Polymorphism and mutation databases Cosmic; 1927245